MP42-08 CAN VESICAL IMAGING-REPORTING AND DATA SYSTEM DIFFERENTIATE T1 AND T2 BLADDER TUMORS? A META-ANALYSIS

Abstract

You have accessJournal of UrologyCME1 May 2022MP42-08 CAN VESICAL IMAGING-REPORTING AND DATA SYSTEM DIFFERENTIATE T1 AND T2 BLADDER TUMORS? A META-ANALYSIS Seyed Behzad Jazayeri, Hojat Dehghanbanadaki, Seyed Behnam Jazayeri, Mahdie Hosseini, Pourya Taghipour, Muhammad Umar Alam, K.C. Balaji, and Mark Bandyk Seyed Behzad JazayeriSeyed Behzad Jazayeri More articles by this author , Hojat DehghanbanadakiHojat Dehghanbanadaki More articles by this author , Seyed Behnam JazayeriSeyed Behnam Jazayeri More articles by this author , Mahdie HosseiniMahdie Hosseini More articles by this author , Pourya TaghipourPourya Taghipour More articles by this author , Muhammad Umar AlamMuhammad Umar Alam More articles by this author , K.C. BalajiK.C. Balaji More articles by this author , and Mark BandykMark Bandyk More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002608.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The value of Vesical Imaging-Reporting and Data System (VIRADS), a structured scoring system of bladder MRI, is in adjudicating transurethral resection of bladder tumors in which there is lamina propria invasion (pT1) and there is concern about unrecognized muscle invasion. In this case, VIRADS could guide to differentiate between pT1 and pT2 bladder cancer; however, no study has investigated the accuracy of VIRADS for detection of muscle invasion in this borderline population. In this study, we aimed to investigate the diagnostic accuracy of VIRADS for distinguishing T2 from T1 bladder cancer using the raw data of previous studies. METHODS: We systematically searched PubMed, Embase, Scopus, and Web of Science up to October 4th 2021 for studies on VIRADS. We included cohort studies on bladder cancer population with index test of VIRADS, reference test of pathology from cystectomy or re-TURBT, and adequate data of VIRADS for patients with only pathologic stages of T1 and T2. We obtained 6 eligible studies for quantitative analysis. The statistical analyses including ROC curve analysis were performed by MIDAS module with STATA. RESULTS: The data derived from 6 included studies on 624 MRI reports of patients with T1 and T2 bladder cancer is depicted in Table 1 and Figure 1. The pooled analysis showed that VIRADS≥3 guaranteed 0.93 (95% CI: 0.91-0.95) accuracy, 93% (95% CI: 85-97%) sensitivity, 61% (95% CI: 30-86%) specificity for differentiation between T1 and T2 bladder cancer while VIRADS≥4 had an accuracy of 0.75 (95% CI: 0.71-0.79), sensitivity of 72% (95% CI: 60-81%), and specificity of 83% (95% CI: 36-98%) in this instance. Nevertheless, the funnel plot asymmetry test showed publication bias for VIRADS≥3 (p<0.01) and VIRADS≥4 (p=0.03). CONCLUSIONS: VIRADS, especially at a cutoff of 3, has high sensitivity and specificity in detecting muscle invasion. None of the patients with VIRADS 1 had muscle invasion in the study. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e733 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Seyed Behzad Jazayeri More articles by this author Hojat Dehghanbanadaki More articles by this author Seyed Behnam Jazayeri More articles by this author Mahdie Hosseini More articles by this author Pourya Taghipour More articles by this author Muhammad Umar Alam More articles by this author K.C. Balaji More articles by this author Mark Bandyk More articles by this author Expand All Advertisement PDF DownloadLoading ...